AMA. V. Makevnina

A. V. Makevnina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. V. Makevnina has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of the utility of hematological indices in monitoring rheumatoid arthritis activity in patients receiving treatment with the direct interleukin 6 inhibitor olokizumab

    by M. A. Korolev, D. A. Yudina, S. Yu. Davidyan, A. Yu. Doroshevskaya, A. V. Makevnina, L. B. Pak, I. G. Bannikova, K. P. Morozova, E. V. Kalinina, E. A. Bogdanova, et al.

    Hematological indices (HIs) are informative, cost-effective, and easy-to-calculate markers for monitoring rheumatoid arthritis (RA) activity. Objective : to analyze the utility of the following hematological indices: neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for monitoring RA activity in patients receiving treatment with the direct interleukin (IL) 6 inhibitor olokizumab (OKZ). Material and methods . The study included 866 patients with RA who initiated OKZ therapy in 2023–2024 and continued treatment for at least 12 months. RA activity parameters, including DAS28-CRP, CDAI, ESR, CRP, NLR, and PLR, were assessed at baseline and at 3, 6, and 12 months after initiation of OKZ therapy. Statistical analysis was performed using generally accepted nonparametric methods. Differences were considered statistically significant at pResults and discussion . At baseline, a lower NLR value was associated with female sex, shorter RA duration, lower ESR and CRP levels, and a reduced need for glucocorticoids (GCs). A lower baseline PLR value was associated with lower ESR and CRP levels and lower DAS28-CRP and CDAI values. A reduction in NLR during the first 3 months of OKZ therapy was associated with achieving remission by month 6 (DAS28-CRP: odds ratio 1.20; 95% confidence interval 1.07–1.35; p=0.002). Lower baseline NLR levels reflected the possibility of more rapid GC withdrawal. OKZ treatment resulted in neutropenia in 2.3% of cases and thrombocytopenia in 3.1%; these events were mild and did not require discontinuation of OKZ. Conclusion. The findings confirm the utility of HIs in assessing RA activity. Changes in NLR at the beginning of OKZ therapy may be considered a predictor of achieving remission/low disease activity, as well as of the possibility of GC withdrawal in patients with RA.

  • Open Access

    Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence

    by P. A. Shesternya, A. I. Zagrebneva, O. V. Antipova, Yu. V. Arbuzova, I. G. Bannikova, L. V. Belozertseva, E. A. Bogdanova, S. A. Bykova, E. A. Vasilenko, I. B. Vinogradova, et al.

    Objective: To study the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) in real-life clinical practice.Material and methods. The observational program was conducted in 73 centers across Russia from Dec 1, 2022 to Jan 31, 2025. It was based on a retrospective analysis of real clinical practice data. Information on patients was collected and analyzed at baseline and after 1, 6, and 12 months of treatment.Results and discussion. A total of 1,576 patients (81.7% women) with RA, aged 55.0 [44.0; 63.0] years and with RA duration of 100.0 [50.0; 156.0] months, were included in the program. After 6 and 12 months of OKZ therapy, the treatment target (remission/low activity) was achieved in 63.3% and 79.8% of patients by DAS28-CRP, and in 55.4% and 75.5% by CDAI respectively. Gender, age, seropositivity, and use of biologic disease-modifying antirheumatic drugs did not significantly affect the achievement of the treatment goal. During the observation period, a significant proportion of patients were able to discontinue glucocorticoids (GCs): 51.1% of patients received GCs initially, after 6 months, 27.6% of patients still received GCs, and after 12 months, 17.0%. During the observation, OKZ treatment was discontinued in 148 (9.5%) patients: in 50 (3.2%) patients due to insufficient efficacy, in 63 (4.0%) patients due to adverse events, and in 35 (2.2%) patients due to other reasons. Conclusion. IL-6 inhibition with OKZ is both effective and safe for achieving RA therapy goals in real-world clinical settings.